Physician profile
Narendra Desai
NPI 1265495113
$2,066.27
in general payments reported to CMS, 2019-2025
15 companies · $62.62 in 2025
The $62.62 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $107 · 2021: $295 · 2022: $373 · 2023: $546 · 2024: $273 · 2025: $62.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $567.62 | 2021-2024 | Jardiance, Spiriva, Synjardy |
| Janssen Pharmaceuticals, INC | $375.66 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $361.31 | 2019-2025 | Farxiga, Lokelma |
| Amarin Pharma, INC. | $158.95 | 2019-2023 | |
| Biotronik INC. | $131.00 | 2019-2021 | |
| Boston Scientific Corporation | $78.09 | 2023 | Watchman Access System |
| Sanofi-Aventis U.S. LLC | $70.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $68.29 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $62.83 | 2021-2022 | |
| Mannkind Corporation | $59.40 | 2019 | |
| Glaxosmithkline, LLC. | $39.44 | 2019-2020 | |
| Pfizer INC. | $29.96 | 2019 | |
| Merck Sharp & Dohme LLC | $24.99 | 2019 | |
| Amgen INC. | $20.95 | 2023 | Repatha |
| Astellas Pharma US INC | $16.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narendra Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.